drugset / Trial / NCT01255709

Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS

NCT01255709

Phase 2 Completed 24 enrolled Amphastar Pharmaceuticals, Inc.
RandomizedCrossoverTriple-blindTreatment

Summary

This study examines the pharmacokinetic profile of Armstrong's proposed Epinephrine Inhalation Aerosol USP, an HFA134a propelled Metered Dose Inhaler (MDI) (E004), using a stable isotope deuterium-labeled epinephrine (epinephrine-d3) to differentiate the administered drug from the endogenous epinephrine, in healthy male and female adult volunteers.

Timeline

Start
2010-12
Primary completion
2011-01
Completion
2011-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Epinephrine Other / unclassified 90 ug Inhaled
Subject Epinephrine Other / unclassified 100 ug Inhaled
Subject Epinephrine Other / unclassified 220 ug Inhaled

Indications